Anti-inflammatory and pro-resolving properties of benzo-lipoxin A4 analogs

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 81, Issue 5-6, 2009, Pages 357-366

  Sun, Yee Ping ^a   Tjonahen, Eric ^a   Keledjian, Raquel ^b   Zhu, Min ^b   Yang, Rong ^a,b   Recchiuti, Antonio ^a   Pillai, Padmini S ^a   Petasis, Nicos A ^b   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Eicosanoids; Inflammation; Neutrophils; Resolution

Indexed keywords

AUTACOID; BENZOLIPOXIN; G PROTEIN COUPLED RECEPTOR; ICOSANOID; LIPOXIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME STABILITY; HINDLIMB; IN VIVO STUDY; LIMB ISCHEMIA; LIPOGENESIS; LUNG INJURY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; REDUCTION; REPERFUSION INJURY; THERMOSTABILITY;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EICOSANOIDS; INFLAMMATION; LIPOXINS; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MODELS, BIOLOGICAL; PERITONITIS; RECEPTORS, FORMYL PEPTIDE; REMISSION INDUCTION;

MURINAE;

EID: 71749109793     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2009.09.004     Document Type: Article

References (41)

1. Majno G., and Joris I. Cells, Tissues and Disease: Principles of General Pathology (1996), Blackwell Science, Cambridge, MA p. 974
2. Nathan C. Points of control in inflammation. Nature 420 (2002) 846-852
3. Serhan C.N., and Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6 (2005) 1191-1197
4. Serhan C.N. Resolution phases of inflammation: novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu. Rev. Immunol. 25 (2007) 101-137
5. Gilroy D.W., Lawrence T., Perretti M., and Rossi A.G. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3 (2004) 401-416
6. 4 block allergen-induced eosinophil trafficking. J. Immunol. 164 (2000) 2267-2271
7. McMahon B., and Godson C. Lipoxins: endogenous regulators of inflammation. Am. J. Physiol. Renal Physiol. 286 (2004) F189-F201
8. 4. Nat. Med. 8 (2002) 1018-1023
9. Fiorucci S., De Lima Jr. O.M., Mencarelli A., et al. Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology 123 (2002) 1598-1606
10. Karp C.L., Flick L.M., Park K.W., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5 (2004) 388-392
11. C.N. Serhan (guest ed.), Special issue on lipoxins and aspirin-triggered lipoxins, Prostaglandins Leukot. Essent. Fatty Acids 73 (3-4) (2005) 139-321.
12. 4 metabolic inactivation. J. Biol. Chem. 275 (2000) 25372-25380
13. 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34 (1995) 14609-14615
14. Schottelius A.J., Giesen C., Asadullah K., et al. An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile. J. Immunol. 169 (2002) 7063-7070
15. Guilford W.J., Bauman J.G., Skuballa W., et al. Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J. Med. Chem. 47 (2004) 2157-2165
16. 4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl. Acad. Sci. USA 101 (2004) 15736-15741
17. 4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg. Med. Chem. Lett. 18 (2008) 1382-1387
18. O'Sullivan T.P., Vallin K.S., Shah S.T., et al. Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J. Med. Chem. 50 (2007) 5894-5902
19. 4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 104 (1999) 309-316
20. Hong S., Porter T.F., Lu Y., Oh S.F., Pillai P.S., and Serhan C.N. Resolvin E1 metabolome in local inactivation during inflammation-resolution. J. Immunol. 180 (2008) 3512-3519
21. Chiang N., Serhan C.N., Dahlén S.-E., et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58 (2006) 463-487
22. Ye R.D., Boulay F., Wang J.M., et al. International Union of Basic and Clinical Pharmacology LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61 (2009) 119-161
23. Olson K.R., and Eglen R.M. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev. Technol. 5 (2007) 137-144
24. Pierce K.L., Premont R.T., and Lefkowitz R.J. Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3 (2002) 639-650
25. Bannenberg G., Moussignac R.-L., Gronert K., et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br. J. Pharmacol. 143 (2004) 43-52
26. Bannenberg G.L., Chiang N., Ariel A., et al. Molecular circuits of resolution: Formation and actions of resolvins and protectins. J. Immunol. 174 (2005) 4345-4355
27. Schwab J.M., Chiang N., Arita M., and Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 (2007) 869-874
28. 4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells. J. Immunol. 170 (2003) 2688-2694
29. 4 inhibit tumor necrosis factor 1a-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189 (1999) 1923-1929
30. Serhan C.N., Chiang N., and Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8 (2008) 249-261
31. S. Krishnamoorthy, A. Recchiuti, N. Chiang, et al., Resolvin D1 binds human phagocytes: Evidence for pro-resolving receptors, submitted for publication.
32. 4 receptor. J. Biol. Chem. 272 (1997) 6972-6978
33. Clish C.B., O'Brien J.A., Gronert K., Stahl G.L., Petasis N.A., and Serhan C.N. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl. Acad. Sci. USA 96 (1999) 8247-8252
34. Gelman S. The pathophysiology of aortic cross-clamping and unclamping. Anesthesiology 82 (1995) 1026-1060
35. In: Baggiolini, Dewald, Moser, Gallin J.I., and Snyderman R. (Eds). Inflammation: Basic Principles and Clinical Correlates (1999), Lippincott Williams and Wilkins, Philadelphia 419-431
36. Olsen N.J., and Stein C.M. New drugs for rheumatoid arthritis. N Engl. J. Med. 350 (2004) 2167-2179
37. Podolsky D.K. Inflammatory bowel disease. N Engl. J. Med. 347 (2002) 417-429
38. 4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183 (1996) 137-146
39. Godson C., Mitchell S., Harvey K., Petasis N.A., Hogg N., and Brady H.R. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164 (2000) 1663-1667
40. Morris T., Stables M., Hobbs A., et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183 (2009) 2089-2096
41. Nokami J., Furukawa A., Okuda Y., Hazato A., and Kurozumi S. Palladium-catalyzed coupling reactions of bromobenzaldehydes with 3,4-di(tert-butyldimethylsilyloxy)-1-alkene to (3,4-dihydroxyalkenyl)benzaldehydes in the synthesis of lipoxin analogues. Tetrahedron Lett. 39 (1998) 1005-1008